Polycystic Ovary Syndrome: A Literature Review With a Focus on Diagnosis, Pathophysiology, and Management
Open Access
- 20 October 2023
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 15 (10) , e47408
Abstract
In females with polycystic ovarian syndrome (PCOS), the most prevalent endocrine condition is chronic anovulation and hyperandrogenism. This illness influences females from conception to death, posing several risks to the health of a female, thus reducing the quality of life. It also increases the rates of mortality and morbidity. The first years of puberty are when PCOS symptoms first show. Menstrual irregularities, anovulation, and acne are features of both PCOS and typical puberty in females. There are many various phenotypes that fall under the same illness, so it is necessary to examine each one independently because they may need different treatments and result in different outcomes. Depending on the diagnostic criteria, approximately 6%-20% of females in the reproductive age group are believed to be affected by PCOS. As long as PCOS is still a syndrome, no single diagnostic indicator, such as hyperandrogenism or polycystic ovary (PCO), can be used to make a clinical diagnosis. The management of females with PCOS depends on the symptoms. These could include menstruation problems, androgen-related symptoms, or infertility caused by ovulatory disruption. In females with PCOS, anovulation is linked to low follicle-stimulating hormone (FSH) levels and a halt in antral follicle growth during the last stages of maturation. The condition may be treated surgically with laparoscopic ovarian drilling or medically with medications such as aromatase inhibitors, metformin, glucocorticoids, clomiphene citrate (CC), tamoxifen, or gonadotropins. Patients will experience different androgenic symptoms, such as hirsutism, acne, and/or baldness. Patients who appear with these troubling symptoms need to receive appropriate care. The review emphasizes the role it plays in the management of various conditions.Keywords
This publication has 36 references indexed in Scilit:
- Use of the Aromatase Inhibitor Letrozole for Ovulation Induction in Women With Polycystic Ovarian SyndromeClinical Obstetrics and Gynecology, 2011
- Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistanceCurrent Opinion in Obstetrics and Gynecology, 2009
- The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force reportFertility and Sterility, 2009
- Insulin Modulation of Luteinizing Hormone Secretion in Normal Female Volunteers and Lean Polycystic Ovary Syndrome PatientsNeuroendocrinology, 2008
- Follicle dynamics and anovulation in polycystic ovary syndromeHuman Reproduction Update, 2008
- New advances in ovulation inductionCurrent Opinion in Obstetrics and Gynecology, 2007
- Single-dose administration of an aromatase inhibitor for ovarian stimulationFertility and Sterility, 2005
- Role of Brain Insulin Receptor in Control of Body Weight and ReproductionScience, 2000
- Insulin Resistance — Mechanisms, Syndromes, and ImplicationsNew England Journal of Medicine, 1991
- Selective Insulin Action on Skin, Ovary, and Heart in Insulin-Resistant StatesDiabetes Care, 1988